Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs tocilizumab in children with systemic juvenile idiopathic arthritis
jRCT2080224972Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of baricitinib in systemic juvenile idiopathic arthritis (SJIA) (3 arms), sponsored by Eli Lilly and Company. Started Dec 2019; status: recruiting.
02
Drugs
baricitinib
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on jRCT2080224972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224972.